Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Wockhardt Limited    WOCKPHARMA   INE049B01025

WOCKHARDT LIMITED

(WOCKPHARMA)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
09/09/2019 09/11/2019 09/12/2019 09/13/2019 09/16/2019 Date
242.75(c) 291.3(c) 324.3(c) 314.8(c) 326.8 Last
397 230 2 712 010 8 770 371 2 992 749 4 664 574 Volume
+1.65% +20.00% +11.33% -2.93% +3.81% Change
More quotes
Financials (INR)
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 -
Capi. / Sales2019 -
Capitalization 36 188 M
More Financials
Company
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. Its products include Ace Proxyvon, Bio-Corneum, Aceroc,... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Latest news on WOCKHARDT LIMITED
08/15WOCKHARDT : Q1FY20 sales at Rs. 863 crore, EBITDA up by 93% in Q1 FY 20 at Rs.56..
AQ
05/14APPROVAL STATUS BY UK MHRA FOR BHIMP : Wockhardt
AQ
05/07WOCKHARDT : FY 19 sales at Rs. 4,158 crore, up by 6% Q4FY19 Net Sales at Rs.979 ..
AQ
05/07WOCKHARDT : loss narrows to Rs 14 crore in Q4, sales decline 4%
AQ
04/11WOCKHARDT : Receives us fda approval for cancer drug 10th april 2019
AQ
03/04WOCKHARDT : Receives us fda approval for prostate cancer drug
AQ
01/29WOCKHARDT : Q3FY19 Net Sales at Rs.1,046 crore, up by 4% over Q3FY18
AQ
01/22WOCKHARDT : Receives us fda approval for leukemia drug
AQ
01/22WOCKHARDT : gets USFDA nod for generic cancer drug
AQ
01/21WOCKHARDT : gets USFDA nod for generic cancer drug 
AQ
More news
Analyst Recommendations on WOCKHARDT LIMITED
More recommendations
Sector news : Generic Pharmaceuticals
10:50aThe U.S. opioid epidemic in the courts
RE
10:01aALLERGAN : Form 8.3 - Allergan Plc
DJ
08:10aASTRAZENECA : FDA Grants Fast Track Designation for Farxiga in Heart Failure
DJ
08:02aJOHNSON & JOHNSON : J&J's Janssen Seeks FDA OK of Tremfya in Active Psoriatic Ar..
DJ
03:27aH LUNDBECK : Lundbeck buys Alder in $2 billion migraine treatment move
RE
More sector news : Generic Pharmaceuticals
Chart WOCKHARDT LIMITED
Duration : Period :
Wockhardt Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WOCKHARDT LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 326,80  INR
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Murtaza Habil Khorakiwala Managing Director & Executive Director
Habil Fakhruddin Khorakiwala Chairman
Anjani Kumar President-Operations
Manas Datta Chief Financial Officer
Venkat Iyer Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
WOCKHARDT LIMITED-39.84%491
OTSUKA HOLDINGS CO LTD6.31%23 590
SUN PHARMACEUTICAL INDUSTRIES-1.78%14 295
SHANGHAI FOSUN PHARMACEUTICAL GROUP17.96%9 451
ONO PHARMACEUTICAL CO., LTD.-7.97%9 435
ZHEJIANG NHU CO LTD--.--%6 807